775 Fed.Appx. 51 (3rd Cir. 2019), 18-2474, Vizirgianakis v. Aeterna Zentaris, Inc.
|Citation:||775 Fed.Appx. 51|
|Opinion Judge:||SILER, Circuit Judge.|
|Party Name:||Gregory VIZIRGIANAKIS; Phong Thomas Dinh; Jamshid Khodavandi v. AETERNA ZENTARIS, INC.; Juergen Engel; David A. Dodd; Paul Blake; Nicholas J. Pelliccione Appellants|
|Attorney:||James E. Cecchi, Esq., Donald A. Ecklund, Esq., Carella Byrne Cecchi Olstein Brody & Agnello, Roseland, NJ, Christopher R. Fallon, Esq., Kevin Ruf, Esq., Kara M. Wolke, Esq., Glancy Prongay & Murray, Los Angeles, CA, Laurence M. Rosen, Esq., South Orange, NJ, for Plaintiffs-Appellees Austin A. Ev...|
|Judge Panel:||Before: CHAGARES, HARDIMAN, and SILER, JR., Circuit Judges|
|Case Date:||May 30, 2019|
|Court:||United States Courts of Appeals, Court of Appeals for the Third Circuit|
Submitted under Third Circuit L.A.R. 34.1(a) April 2, 2019
This opinion is not regarded as Precedents which bind the court under Third Circuit Internal Operating Procedure Rule 5.7. (See Federal Rule of Appellate Procedure Rule 32.1)
On Appeal from the United States District Court for the District of New Jersey (No. 3:14-cv-07081), District Judge: Hon. Peter G. Sheridan
James E. Cecchi, Esq., Donald A. Ecklund, Esq., Carella Byrne Cecchi Olstein Brody & Agnello, Roseland, NJ, Christopher R. Fallon, Esq., Kevin Ruf, Esq., Kara M. Wolke, Esq., Glancy Prongay & Murray, Los Angeles, CA, Laurence M. Rosen, Esq., South Orange, NJ, for Plaintiffs-Appellees
Austin A. Evans, Esq., King & Spalding, Atlanta, GA, Felice B. Galant, Esq., Norton Rose Fulbright, New York, NY, Gerard G. Pecht, Esq., Norton Rose Fulbright, Houston, TX, for Defendant-Appellant Juergen Engel
Jeffrey S. Bucholtz, Esq., Joshua N. Mitchell, Esq., King & Spalding, Washington, DC, Austin A. Evans, Esq., Brandon Keel, Esq., B. Warren Pope, Esq., Michael R. Smith, Esq., King & Spalding, Atlanta, GA, for Defendants-Appellants Nicholas J. Pelliccione
Before: CHAGARES, HARDIMAN, and SILER, JR.,[*] Circuit Judges
SILER, Circuit Judge.
Pursuant to Federal Rule of Civil Procedure 23(f), defendants Aeterna Zentaris, Inc., and its named former employees,1 appeal the district courts order granting class certification in this securities action. We will affirm the decision of the district court.
We write for the parties and relate only the necessary facts. In 2009, the biopharmaceutical company Aeterna acquired the rights to AEZS-130, a drug in development it sought to have approved for commercialization by the Food and Drug Administration ("FDA"). To this end, Aeterna agreed to continue an ongoing study of the drug according to the terms of a Special Protocol Assessment ("SPA"), an agreement between Aeterna and the FDA regarding how the study should be completed to show the drugs safety and efficacy.
According to the complaint, Aeterna issued numerous press releases and other statements indicating that the study showed the drug was effective in accordance with the protocol agreed to...
To continue readingFREE SIGN UP